European commission approves adcetris® (brentuximab vedotin) for the treatment of adult patients with newly diagnosed stage iib/iii/iv hodgkin lymphoma in combination with ecadd

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that the european commission (ec) approved adcetris® (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ecadd) – a chemotherapy regimen – in adult patients with newly diagnosed stage iib with risk factors/iii/iv hodgkin lymphoma. the decision follows a positive opinion from the committee for medicinal products for human use (chmp) on april.
TAK Ratings Summary
TAK Quant Ranking